Arc-1 review

Arc-1 lists sermorelin variants as available in its public catalog and advertises a subscription from $239.99/month. Catalog stock does not guarantee a prescription or establish your first charge and supply. The homepage carries a construction notice, and the generic return policy leaves prescription refund rights unresolved.

Arc-1 is a longevity storefront whose legal pages identify Arc-1 Metrics, PLLC of Las Vegas, Nevada. The seller names Todd A. Stearns as founder and presents physician and certification claims; these disclosures are not independent credential verification. Its menu spans sermorelin, NAD⁺ injection and nasal spray, glutathione, rapamycin, metformin, enclomiphene, B12, ED medication and compounded weight-loss products. It advertises a $0 consultation, free expedited shipping and a 30-day satisfaction guarantee.

The product page describes checkout followed by intake and provider evaluation; a prescription is conditional. Sermorelin excludes Arkansas, Indiana, Minnesota, Puerto Rico and South Carolina. NAD⁺ injection and nasal spray also exclude California. Confirm treatment-specific eligibility, lab requirements and costs, and the dispensing pharmacy.

Support describes account-based refill management, delivery and payment changes, and lab-result access. It does not establish the cancellation cutoff or included monitoring for a particular plan.

The public catalog lists sermorelin variants at $299.99 and $399.99 as available, with a subscription advertised from $239.99/month and $60 off refills. NAD⁺ injection is listed at $299.99 per product, separately advertising a subscription from $239.99/month. Nasal NAD⁺ is $149.99 per product, with a subscription advertised from $94.99/month. Confirm the selected variant, first debit, prescribed supply and renewal; base product prices do not establish calendar-month costs.

The generic return policy requires a request within 30 days of receipt, unused goods in original packaging with tags, proof of purchase and advance approval. Refunds follow inspection and approval and can take six to eight weeks. This retail language does not establish prescription returns, medical-denial refunds or refunds of unused prepaid periods. Obtain the prescription-specific terms and cancellation deadline before paying.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The compounded products are pharmacy preparations, not therapeutically equivalent to branded drugs, and the site says only "US-licensed pharmacies" without naming one. The menu needs unpacking by evidence tier rather than read as a single longevity stack. Sermorelin acts on the growth-hormone axis, a real mechanism with thin long-term outcome data. Injectable and intranasal NAD⁺ have no controlled human outcome trials; oral NR and NMN are the studied forms and they raise blood NAD⁺ rather than a demonstrated clinical outcome. Injectable glutathione has essentially no controlled human outcome evidence for the claims made about it. Rapamycin and metformin are approved drugs, for transplant rejection and type 2 diabetes respectively, sold here off-label for longevity; rapamycin extends lifespan in mice, which is a robust animal result and not a human one, and metformin's longevity case rests on observational analyses of diabetic populations that cannot establish benefit in healthy people. Off-label prescribing is legal and often reasonable. It is not evidence of effect. Individual results vary.